Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

BACKGROUND: Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance. PATIENTS AND METHODS: Prospective, multicente...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143095/
https://ncbi.nlm.nih.gov/pubmed/25122671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados